MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine agonists"

  • 2019 International Congress

    Abnormal posture during treatment of restless legs syndrome in an old woman: A case report

    K. Hirata, K. Suzuki, M. Saito, T. Shiina, H. Sakuramoto, M. Hamaguchi, T. Kadowaki (Mibu, Japan)

    Objective: To report a patient with restless legs syndrome (RLS) in whom abnormal posture appeared during treatment of that. Background: Abnormal posture such as camptocormia…
  • 2019 International Congress

    Restless Genital Syndrome in a patient with Dementia with Lewy Body

    M. Abu Al-Melh, M. Farghal, B. Al-Failakawii (Kuwait, Kuwait)

    Objective: To report the co-existence of Restless Genital Syndrome (RGS) and Dementia with Lewy Body (DLB), and to highlight the responsiveness to rotigotine (dopamine agonist)…
  • 2019 International Congress

    Trends in first line therapy for PD in Wales: A 16 year observational study

    K. Orayj, A. Lacey, A. Akbari, O. Pickrell, E. Lane (Cardiff, United Kingdom)

    Objective: To examine the changes in first line therapy of newly diagnosed Parkinson’s patients between 2000 and 2016 in Wales. Background: There have been several…
  • 2019 International Congress

    Parkinson’s disease polygenic risk score is not associated with impulse control disorders: a longitudinal study

    J. Ihle, F. Artaud, S. Bekadar, G. Magnone, H. Bertrand, S. Sambin, LL. Mariani, C. Scherzer, A. Elbaz, JC. Cornol (Paris, France)

    Objective: To examine the relationship between a polygenic risk score (GRS) associated with Parkinson’s disease (PD) and impulse control disorders (ICDs) in PD. Background: Genome…
  • 2019 International Congress

    Impulse control disorders and (romantic) jealousy in Parkinson’s disease: a patients’ vs. partners’ perspective

    E. Pipan, S. Delalić, A. Herzog, M. Trošt, Z. Pirtošek, D. Flisar, N. Kovacs, D. Georgiev (Ljubljana, Slovenia)

    Objective: To compare self-reported symptoms of (romantic) jealousy and impulse control disorders (ICD) in Parkinson’s disease (PD) patients to those reported by their partners. Background:…
  • 2019 International Congress

    Longitudinal analysis of the relation between trajectories of dopaminergic agonists use and BMI in Parkinson’s disease

    F. Artaud, PC. Lee, M. Vidailhet, JC. Corvol, A. Elbaz (Saint-Aubin, France)

    Objective: To describe the longitudinal relation between dopaminergic agonists (DA) use and change of BMI in a longitudinal cohort of PD patients followed annually up…
  • 2019 International Congress

    Long-term apomorphine infusion (APO) users versus short-term APO users: What is the reason to discontinue therapy? A multi-centre study

    R. Bhidayasiri, O. Phokaewvarangkul, K. Boonpang, Y. Thongchuam, T. Boonmongkol, P. Garcia Ruiz (Bangkok, Thailand)

    Objective: To evaluate the long-term efficacy of APO in PD patients treated at two specialist centres in Spain and Thailand, and to determine the reasons…
  • 2019 International Congress

    Predictors of refractory impulse control disorder to dopamine agonists substitution therapy in Parkinson’s disease patients

    JY. Lee, J-H. Choi, B. Jeon, J. Cho (Seoul, Republic of Korea)

    Objective: This study was aimed to investigate a predictive factor of refractory impulse control disorder (ICD) in patients with Parkinson’s disease (PD) who participated in…
  • 2019 International Congress

    Olfactory Hallucinations Induced by Pramipexole Treatment in Parkinson’s Disease

    G. Hatipoglu, S. Ozkaynak (Antalya, Turkey)

    Objective: In the treatment of Parkinson’s disease, dopamine agonists are among the preferred treatment options, particularly in the treatment of young Parkinson’s patients. The known…
  • 2019 International Congress

    A study for expanding application sites of rotigotine transdermal patch

    S. Itaya, Y. Choh, M. Takahashi, A. Inaba, K. Orimo, Y. Ono, H. Kujirai, S. Orimo (Tokyo, Japan)

    Objective: We examined to see whether to expand application sites of RTP other than the approved application sites. Background: Rotigotine transdermal patch (RTP) is a dopamine…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #29077 (not found)
  • #29056 (not found)
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28189 (not found)
  • Welcome to the MDS Abstracts Site
  • Advanced Search
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley